$1.565
+0.090 (+5.74%)At close
Technical Sentiment
Overall Consensus
Technical Analysis Consensus
Moving Average Consensus
Inhibikase Therapeutics Inc (IKT) Moving Averages Convergence Divergence (MACD) indicator is -0.14, suggesting IKT is Sell.
Inhibikase Therapeutics Inc (IKT) 20-Day simple moving average is 1.65, while Inhibikase Therapeutics Inc (IKT) share price is $—, making it Sell.
Inhibikase Therapeutics Inc (IKT) 60-Day simple moving average is 2.07, while Inhibikase Therapeutics Inc (IKT) share price is $—, making it Sell.
Technical Analysis for IKT
AI Technical IKTAs of 2026-11-03, the technical board for Inhibikase Therapeutics Inc (IKT) reads sell: 4 indicators are flashing buy, 7 are indicating sell, and 2 are neutral. Price at $1.57 sits below the 20-day, 60-day and 200-day moving averages and above the 5-day and 10-day.
Momentum readings: RSI stands at 33.361, MACD stands at -0.137 (Sell), Stochastic %K stands at 11.494 (Buy), Stochastic %D stands at 12.9 and CCI stands at -108.886 (Buy).
IKT trades below the 60-day SMA (2.07) and below the 200-day SMA (1.93). Immediate resistance sits at Classic R1 1.68, then R2 1.81. Support sits at Classic S1 1.44, then S2 1.32.
Inhibikase Therapeutics Inc (IKT) Support & Resistance Level
Inhibikase Therapeutics Inc (IKT) Technical Indicators
2026-11-03
| Name | Value |
|---|---|
| RSI_14 | 33.361 |
| STOCHk_14_3_3 | 11.494 |
| STOCHd_14_3_3 | 12.900 |
| CCI_20 | -108.886 |
| AO_5_34 | -0.284 |
| MOM_10 | -0.165 |
| MACD_12_26_9 | -0.137 |
Inhibikase Therapeutics Inc (IKT) Relative Strength Index (RSI_14) is 33.361, creating a Neutral signal.
Inhibikase Therapeutics Inc (IKT) Stochastic %K is 11.494, creating a Buy signal.
Inhibikase Therapeutics Inc (IKT) Stochastic %D is 12.900, creating a Buy signal.
Inhibikase Therapeutics Inc (IKT) CCI_20 is -108.886, creating a Buy signal.
Inhibikase Therapeutics Inc (IKT) Awesome Oscillator (AO) is -0.284, creating a Sell signal.
Inhibikase Therapeutics Inc (IKT) Momentum (MOM) is -0.165, creating a Sell signal.
Inhibikase Therapeutics Inc (IKT) Moving Average Convergence Divergence (MACD) is -0.137, creating a Sell signal.
Inhibikase Therapeutics Inc (IKT) Moving Average
2026-11-03
| Period | Simple | Signal |
|---|---|---|
| MA_5 | 1.520 | Buy |
| MA_10 | 1.557 | Buy |
| MA_20 | 1.654 | Sell |
| MA_60 | 2.071 | Sell |
| MA_200 | 1.933 | Sell |
| MA_250 | 1.876 | Sell |
Inhibikase Therapeutics Inc (IKT) 5-Day simple moving average is 1.520, while Inhibikase Therapeutics Inc (IKT) share price is $, making it a Buy.
Inhibikase Therapeutics Inc (IKT) 10-Day simple moving average is 1.557, while Inhibikase Therapeutics Inc (IKT) share price is $, making it a Buy.
Inhibikase Therapeutics Inc (IKT) 20-Day simple moving average is 1.654, while Inhibikase Therapeutics Inc (IKT) share price is $, making it a Sell.
Inhibikase Therapeutics Inc (IKT) 60-Day simple moving average is 2.071, while Inhibikase Therapeutics Inc (IKT) share price is $, making it a Sell.
Inhibikase Therapeutics Inc (IKT) 200-Day simple moving average is 1.933, while Inhibikase Therapeutics Inc (IKT) share price is $, making it a Sell.
Inhibikase Therapeutics Inc (IKT) 250-Day simple moving average is 1.876, while Inhibikase Therapeutics Inc (IKT) share price is $, making it a Sell.
Related articles
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.